Article
Amylyx says European panel unlikely to endorse ALS drug
Rating:
0.0
Views:
30
Likes:
1
Library:
1
Amylyx Pharmaceuticals Inc said on Tuesday that a European regulatory panel had taken a negative view on its amyotrophic lateral sclerosis (ALS) treatment, stalling the company's plans on introducing its first commercial drug in the region.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value